Clinical trials: Alexander Disease
- Condition Alexander Disease
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Alexander Disease
Zilganersen Expanded Access Program for Individuals With Alexander Disease
The purpose of the expanded access program (EAP) is to provide access to zilganersen for eligible individuals with Alexander disease (AxD).
- Trial name
- NCT07487389
- Testing
- zilganersen
- Sponsor
- Ionis Pharmaceuticals, Inc.
Alexander Disease
A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)
The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.
- Trial name
- NCT04849741
- Testing
- zilganersen
- Where
- 13 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- Ionis Pharmaceuticals, Inc.